Huvepharma buys certain assets of Zoetis

23-12-2015 | |
Huvepharma buys certain assets of Zoetis
Huvepharma buys certain assets of Zoetis

Huvepharma, a global animal health company, has agreed to acquire certain assets from Zoetis, which include products and two owned and one leased US manufacturing sites.

The assets associated with this deal involve an international portfolio of medicated feed additives, including Albac® (excluding  the USA market) and  Bio-Cox® / Salinomax® as well as Inovocox®EM1, a leading coccidiosis vaccine for broilers. Along with these products, Huvepharma will acquire and assume manufacturing sites in the US located in Laurinburg, North Carolina and Van Buren, Arkansas.  Other assets included in the acquisition are major brands of water soluble veterinary products; R-Pen®, Oxytet®, Sul –Q-Nox, CTC, Lincomycin, Poultry Sulfa and Neo-Sol® including the formulation facility located in Longmont,  Colorado. Additional pharmaceuticals assets were also acquired that are predominately sold in Europe and include Lincocin Forte®, Stockade®, Bacivet®, Combiotic® and Quadrisol®.  Employees at the three manufacturing sites will be transfered to Huvepharma.

Reinforce growth potential

“We are extremely excited about this acquisition from Zoetis which reinforces and builds upon our commitment to our customers in providing high quality products for livestock, produced in our EU and USA based facilities. Huvepharma remains dedicated to its strategy of creating a fully integrated corporate structure for producing world class products and services for our global customer base.  We are satisfied that the strong brands associated with these assets will continue to strengthen our position in key markets and reinforce our growth potential” says Kiril Domuschiev, President and owner of Huvepharma. “This acquisition advances Huvepharma’s  strategy in the animal health market and further strengthens our current portfolio of products.  It is yet another milestone for our company and we look forward to integrate the products and production sites so we can realize the value these additions will produce for Huvepharma and our customers worldwide.” says Glen Wilkinson, President Huvepharma, USA.

Products are expected to be available from Huvepharma on February 1, 2016 and may continue to be ordered from Zoetis prior to that.

Emmy Koeleman Freelance editor